Clinical Trials Browser

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT04855136 2025-09-11

KarMMa-7

Phase 1/2 Terminated

21 enrolled

Plasma cell

Multiple Myeloma

NCT04735575 2025-05-28

A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

Phase 1/2 Terminated

40 enrolled

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Hematologic Neoplasms

NCT04896658 2025-04-03

Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Terminated

10 enrolled 14 charts

Plasma cell

Multiple Myeloma

NCT01997840 2025-03-04

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Phase 1/2 Terminated

103 enrolled 21 charts

Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Plasma Cell

NCT06655818 2025-03-03

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

Phase 1/2 Terminated

4 enrolled 16 charts

Plasma cell

Multiple Myeloma

NCT04150965 2025-02-14

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Phase 1/2 Terminated

14 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT05427812 2025-01-17

Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Terminated

29 enrolled

Plasma cell

Multiple Myeloma

NCT02002598 2024-09-19

Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma

Phase 1/2 Terminated

23 enrolled 13 charts

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02863991 2024-07-03

Oral ONC201 in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Terminated

17 enrolled 10 charts

Plasma cell

Multiple Myeloma

NCT05000450 2024-06-28

Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1/2 Terminated

6 enrolled

Plasma cell

Multiple Myeloma

NCT01670994 2024-06-18

QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Terminated

6 enrolled 10 charts

Plasma cell

Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Recurrence

NCT02661022 2024-04-17

SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

Phase 1/2 Terminated

9 enrolled 13 charts

Plasma cell

Multiple Myeloma, Recurrence

NCT03288493 2024-03-28

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

Phase 1/2 Terminated

105 enrolled 16 charts

Plasma cell

Multiple Myeloma

NCT06160609 2024-03-12

Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM

Phase 1/2 Terminated

9 enrolled 14 charts

Plasma cell

Multiple Myeloma

NCT01177683 2023-10-06

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Phase 1/2 Terminated

32 enrolled 18 charts

Plasma cell

Multiple Myeloma

NCT03201250 2023-09-08

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

Phase 1/2 Terminated

11 enrolled 11 charts

Plasma cell

Multiple Myeloma

NCT04635735 2023-03-23

Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma

Phase 1/2 Terminated

3 enrolled 5 charts

Plasma cell

Multiple Myeloma

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Phase 1/2 Terminated

201 enrolled 71 charts

BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT03481556 2022-12-19

ANCHOR

Phase 1/2 Terminated

56 enrolled 22 charts

Plasma cell

Multiple Myeloma

NCT01881789 2022-11-14

Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma

Phase 1/2 Terminated

22 enrolled 17 charts

Plasma cell

Multiple Myeloma

NCT01416428 2022-11-08

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

Phase 1/2 Terminated

210 enrolled

LymphoidPlasma cell

Waldenstrom Macroglobulinemia, Multiple Myeloma

NCT01464034 2022-08-01

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Terminated

136 enrolled

Plasma cell

Multiple Myeloma

NCT01555281 2022-07-07

Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma

Phase 1/2 Terminated

33 enrolled

Plasma cell

Multiple Myeloma

NCT03875495 2022-01-28

A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)

Phase 1/2 Terminated

9 enrolled 1 chart

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT04097301 2022-01-19

Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma

Phase 1/2 Terminated

8 enrolled 13 charts

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Leukemia, Myeloid, Acute

NCT02587598 2021-12-08

Study of INCB053914 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

97 enrolled 40 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Lymphoproliferative Disorders, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT01101594 2021-08-16

A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma

Phase 1/2 Terminated

17 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT01946152 2021-07-30

Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Terminated

21 enrolled 14 charts

Plasma cell

Multiple Myeloma

NCT02757326 2021-06-18

ABC-103

Phase 1/2 Terminated

13 enrolled 12 charts

Plasma cell

Multiple Myeloma

NCT03340883 2021-04-01

Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)

Phase 1/2 Terminated

21 enrolled 10 charts

Plasma cell

Multiple Myeloma

NCT03033316 2020-11-06

AMETHYST

Phase 1/2 Terminated

7 enrolled

Plasma cell

Multiple Myeloma

NCT03287804 2020-10-23

APRIL

Phase 1/2 Terminated

12 enrolled 14 charts

Plasma cell

Multiple Myeloma

NCT01832727 2020-07-13

Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Phase 1/2 Terminated

65 enrolled 30 charts

Plasma cell

Multiple Myeloma

NCT00985907 2020-06-17

DMV

Phase 1/2 Terminated

13 enrolled 8 charts

Plasma cell

Multiple Myeloma, Patient Participation, Neoplasms, Plasma Cell

NCT03492138 2020-05-29

Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Terminated

5 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT02756728 2020-03-12

A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma

Phase 1/2 Terminated

5 enrolled

Plasma cell

Multiple Myeloma

NCT02928029 2020-02-26

Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma

Phase 1/2 Terminated

7 enrolled 9 charts

Plasma cell

Multiple Myeloma

NCT03196947 2020-01-30

SMR-3184

Phase 1/2 Terminated

1 enrolled

Plasma cell

Multiple Myeloma

NCT00861965 2020-01-22

Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers

Phase 1/2 Terminated

2 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma

NCT01239368 2019-12-10

Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma

Phase 1/2 Terminated

34 enrolled 17 charts

Plasma cell

Multiple Myeloma

NCT02548962 2019-11-21

Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

Phase 1/2 Terminated

11 enrolled 12 charts

Plasma cell

Multiple Myeloma

NCT02289222 2019-11-05

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Terminated

48 enrolled 10 charts

Plasma cell

Multiple Myeloma, Recurrence

Clinical Trials

GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

CPIT001

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

iinnovate-3

iinnovate-1

INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

LIMBER

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

KarMMa-7

A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma

Oral ONC201 in Relapsed/Refractory Multiple Myeloma

Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

ANCHOR

Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma

A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)

Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma

Study of INCB053914 in Subjects With Advanced Malignancies

A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma

Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma

ABC-103

Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)

AMETHYST

APRIL

Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

DMV

Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma

Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma

SMR-3184

Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers

Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma

Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma